Contrasting Onconetix (NASDAQ:ONCO) & Alnylam Pharmaceuticals (NASDAQ:ALNY)

Onconetix (NASDAQ:ONCO) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Profitability

This table compares Onconetix and Alnylam Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Volatility & Risk

Onconetix has a beta of 2.61, suggesting that its share price is 161% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Institutional and Insider Ownership

23.9% of Onconetix shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.3% of Onconetix shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Onconetix and Alnylam Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1	0	0	0	1.00
Alnylam Pharmaceuticals	0	6	16	3	2.88

Alnylam Pharmaceuticals has a consensus price target of $365.50, indicating a potential upside of 62.83%. Given Alnylam Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Onconetix.

Earnings & Valuation

This table compares Onconetix and Alnylam Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$645,824.00	4.45	-$14.03 million	$248.12	0.00
Alnylam Pharmaceuticals	$3.71 billion	8.09	$313.75 million	$5.38	41.72

Alnylam Pharmaceuticals has higher revenue and earnings than Onconetix. Onconetix is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alnylam Pharmaceuticals beats Onconetix on 13 of the 15 factors compared between the two stocks.

About Onconetix

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.